坎普使用基于体的组合纳米治疗方案改善了结直肠癌免疫化学疗法
Zhiren Wang1, Wenpan Li1, Yanhao Jiang1
1Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, Tucson, AZ, 85721, United States.
在联合输送的纳米纤维 (DOX-IND/Camptothesome) 中优化药物比率增强了癌症治疗,性能优于标准治疗,并且在晚期结直肠癌的免疫检查点封锁方面表现有前途.
科学领域:
- 纳米医学是一种纳米医学.
- 癌症治疗 癌症治疗
- 免疫学 免疫学 免疫学
背景情况:
- 坎普托体 (SM-CSS-CPT) 纳米微粒可以改善药物输送,但可以诱导IDO1负面反.
- 印多克西莫德 (IND) 是一种用于减轻这种反的IDO1抑制剂.
- 来自多克索鲁比的IND (DOX-IND) 已被开发用于联合封装.
研究的目的:
- 为了确定DOX-IND/Camptothesome的最佳协同药物比率.
- 评估优化DOX-IND/Camptothesome对晚期癌症的体内疗效.
- 评估结合疗法与免疫检查点阻塞 (ICB) 的潜力.
主要方法:
- 系统的体外查以确定最佳的DOX-IND/SM-CSS-CPT比率.
- 使用晚期MC38和正位 CT26-Luc瘤的小鼠进行体内研究.
- 与免费药物,其他IDO1抑制剂和标准化疗 (Folfox,Folfiri) 的比较.
- 与免疫检查点阻塞 (ICB) 联合治疗的评估.
主要成果:
- 与单个成分或其他组合相比,优化的DOX-IND/Camptothesome证明了优越的瘤吸收和抗瘤疗效.
- 优化的配方在MC38模型中与ICB相结合时,可以根除60%的大型瘤.
- 它在没有观察到副作用的结直肠癌模型中表现优于Folfox和Folfiri.
- 在CT26-Luc模型中,它与ICB结合时消除了40%的瘤完全转移缓解,增强了抗CRC免疫反应.
结论:
- 精确的协同药物比率对于最大限度地发挥DOX-IND/Camptothesome.some的治疗潜力至关重要.
- 优化的DOX-IND/Camptothesome显示出显著的前景,作为高级结直肠癌的优质治疗方法,特别是与ICB结合使用时.
- 这种基于纳米纤维的疗法需要对癌症患者进行进一步的临床研究.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
08:03Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
相关概念视频
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
